Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 43, Issue , 2017, Pages 1-5

  Emeryk Maksymiuk, Justyna ^a   Emeryk, Andrzej ^a   Krawczyk, Paweł ^a   Wojas Krawczyk, Kamila ^a   Milanowski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antibiotic therapy; Beta 2 adrenoreceptor polymorphism; Beta 2 mimetics; COPD; Exacerbation; Glucocorticosteroids

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR; CORTICOSTEROID; FENOTEROL; FORMOTEROL; GLUCOCORTICOID; SALBUTAMOL; SALMETEROL; ADRB2 PROTEIN, HUMAN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL INDICATOR; CODON; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA ISOLATION; DOWN REGULATION; FEMALE; GENE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HOMOZYGOTE; HOSPITALIZATION; HUMAN; LEUKOCYTE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS BLOOD; GENETICS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADRENAL CORTEX HORMONES; AGED; ANTI-BACTERIAL AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 85009888000     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.01.005     Document Type: Article

References (37)

1. [1] Broadley, K.J., Beta-adrenoceptor responses of the airways: for better or worse?. Eur. J. Pharmacol. 533 (2006), 15–27.
2. [2] From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2015 http://www.ginasthma.org.
3. [3] From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015 http://www.goldcopd.org.
4. [4] Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450 (2007), 383–387.
5. [5] Insel, P.A., β2-Adrenergic receptor polymorphisms and signaling: do variants influence the “memory” of receptor activation?. Sci. Signal., 4, 2011, pe37.
6. [6] Green, S.A., Turki, J., Bejarano, P., Hall, I.P., Liggett, S.B., Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 13 (1995), 25–33.
7. [7] Green, S.A., Turki, J., Innis, M., Liggett, S.B., Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33 (1994), 9414–9419.
8. [8] Liggett, S.B., The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J. Allergy Clin. Immunol. 105 (2000), S487–S492.
9. [9] Qiu, Y., Zhang, D., Qin, Y., Yin, K.S., Effect of β2 -adrenergic receptor gene Arg16Gly polymorphisms on response to long-acting β2-agonist in Chinese Han asthmatic patients. Multidiscip. Respir. Med., 9, 2014, 22.
10. [10] Israel, E., Chinchilli, V.M., Ford, J.G., Boushey, H.A., Cherniack, R., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004), 1505–1512.
11. [11] Hizawa, N., Beta-2 adrenergic receptor genetic polymorphisms and asthma. J. Clin. Pharm. Ther. 34 (2009), 631–643.
12. [12] Lee, D.K., Currie, G.P., Hall, I.P., Lima, J.J., Lipworth, B.J., The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol. 57 (2004), 68–75.
13. [13] Palmer, C.N., Lipworth, B.J., Lee, S., Ismail, T., Macgregor, D.F., et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61 (2006), 940–944.
14. [14] Taylor, D.R., Drazen, J.M., Herbison, G.P., Yandava, C.N., Hancox, R.J., et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55 (2000), 762–767.
15. [15] Wechsler, M.E., Lehman, E., Lazarus, S.C., Lemanske, R.F. Jr., Boushey, H.A., et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 173 (2006), 519–526.
16. [16] Bleecker, E.R., Meyers, D.A., Bailey, W.C., Sims, A.M., Bujac, S.R., et al. ADRB2 polymorphism and budesonide/formoterol response in chronic obstructive pulmonary disease. Chest 142 (2012), 320–328.
17. [17] Hizawa, N., Makita, H., Nasuhara, Y., Betsuyaku, T., Itoh, Y., et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 132 (2007), 1485–1492.
18. [18] Kim, W.J., Oh, Y.M., Sung, J., Kim, T.H., Huh, J.W., et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 186 (2008), 381–386.
19. [19] Konno, S., Makita, H., Hasegawa, M., Nasuhara, Y., Nagai, K., et al. Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to beta2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease. Pharmacogenet Genomics 21 (2011), 687–693.
20. [20] Yelensky, R., Li, Y., Lewitzky, S., Leroy, E., Hurwitz, C., et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J. 12 (2012), 484–488.
21. [21] Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., et al. Interpretative strategies for lung function tests. Eur. Respir. J. 26 (2005), 948–968.
22. [22] National Center for Biotechnology Information, www.ncbi.nih.gov/snp.
23. rd. 2010.
24. [24] Kips, J.C., Pauwels, R.A., Long-acting inhaled β2-agonist therapy in asthma. Am. J. Respir. Crit. Care Med. 164 (2001), 923–932.
25. [25] Salpeter, S.R., Ormiston, T.M., Salpeter, E.E., Tolerance to beta2-agonist treatment after regular use in people with asthma. Ann. Intern. Med. 140 (2004), 802–813.
26. [26] Haney, S., Hancox, R.J., Rapid onset of tolerance to beta-agonist bronchodilation. Resp. Med. 99 (2005), 566–571.
27. [27] Vacca, G., Schwabe, K., Duck, R., Hlawa, H.P., Westphal, A., et al. Polymorphisms of the beta2 adrenoreceptor gene in chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 3 (2009), 3–10.
28. [28] Bleecker, E.R., Postma, D.S., Lawrance, R.M., Meyers, D.A., Ambrose, H.J., et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 3709 (2007), 2118–2125.
29. [29] January, B., Seibold, A., Whaley, B., Hipkin, R.W., Lin, D., et al. Beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J. Biol. Chem. 272 (1997), 23871–23879.
30. [30] Pauwels, R.A., Loefdahl, C.G., Postma, D.S., Tattersfield, A.E., O'Byrne, P., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids Establishing therapy (FACET) International study group. N. Engl. J. Med. 337 (1997), 1405–1411.
31. [31] Ullman, A., Hedner, J., Svedmyr, N., Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am. Rev. Respir. Dis. 142 (1990), 571–575.
32. [32] Schmidt, M., Michel, M.C., How can 1 + 1 = 3? β2-adrenergic and glucocorticoid receptor agonist synergism in obstructive airway diseases. Mol. Pharmacol. 80 (2011), 955–958.
33. [33] Rebordosa, C., Kogevinas, M., Guerra, S., Castro-Giner, F., Jarvis, D., Cazzoletti, L., et al. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. Eur. Respir. J. 38 (2011), 1029–1035.
34. [34] Rabe, K.F., Fabbri, L.M., Israel, E., Kögler, H., Riemann, K., Schmidt, H., et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir. Med. 2 (2014), 44–53.
35. [35] Hall, I.P., Blakey, J.D., Al Balushi, K.A., Wheatley, A., Sayers, I., Pembrey, M.E., et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 368 (2006), 771–779.
36. [36] Thomsen, M., Nordestgaard, B.G., Sethi, A.A., Tybjærg-Hansen, A., Dahl, M., Beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur. Respir. J. 39 (2012), 558–566.
37. [37] Weir, T.D., Mallek, N., Sandford, A.J., Bai, T.R., Awadh, N., et al. Beta2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am. J. Respir. Crit. Care Med. 158 (1998), 787–791.